1. BaizeS, PannetierD, OestereichL, RiegerT, KoivoguiL, et al. (2014) Emergence of Zaire Ebola Virus Disease in Guinea - Preliminary Report. N Engl J Med
2. Du ToitA (2014) Ebola virus in West Africa. Nat Rev Microbiol 12: 312.
3. LigonBL (2005) Outbreak of Marburg hemorrhagic fever in Angola: a review of the history of the disease and its biological aspects. Semin Pediatr Infect Dis 16: 219–224.
4. MohamadzadehM (2009) Potential factors induced by filoviruses that lead to immune supression. Curr Mol Med 9: 174–185.
5. MahantyS, BrayM (2004) Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 4: 487–498.
6. MehediM, GrosethA, FeldmannH, EbiharaH (2011) Clinical aspects of Marburg hemorrhagic fever. Future Virol 6: 1091–1106.
7. FeldmannH, NicholST, KlenkHD, PetersCJ, SanchezA (1994) Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 199: 469–473.
8. Feldmann H, Klenk HD, Sanchez A (1993) Molecular biology and evolution of filoviruses. Arch Virol Suppl 7: 81–100.
9. SanchezA, KileyMP, HollowayBP, AuperinDD (1993) Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res 29: 215–240.
10. VolchkovaVA, FeldmannH, KlenkHD, VolchkovVE (1998) The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer. Virology 250: 408–414.
11. SanchezA, TrappierSG, MahyBW, PetersCJ, NicholST (1996) The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc Natl Acad Sci U S A 93: 3602–3607.
12. VolchkovVE, FeldmannH, VolchkovaVA, KlenkHD (1998) Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 95: 5762–5767.
13. FalzaranoD, KrokhinO, Wahl-JensenV, SeebachJ, WolfK, et al. (2006) Structure-function analysis of the soluble glycoprotein, sGP, of Ebola virus. Chembiochem 7: 1605–1611.
14. VolchkovaVA, KlenkHD, VolchkovVE (1999) Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology 265: 164–171.
15. VolchkovVE (1999) Processing of the Ebola virus glycoprotein. Curr Top Microbiol Immunol 235: 35–47.
16. JeffersSA, SandersDA, SanchezA (2002) Covalent modifications of the ebola virus glycoprotein. J Virol 76: 12463–12472.
17. Alazard-DanyN, VolchkovaV, ReynardO, CarbonnelleC, DolnikO, et al. (2006) Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J Gen Virol 87: 1247–1257.
18. LeeJE, FuscoML, HessellAJ, OswaldWB, BurtonDR, et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454: 177–182.
19. MartinezO, TantralL, MulherkarN, ChandranK, BaslerCF (2011) Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis 204 Suppl 3S825–832.
20. ReynardO, BorowiakM, VolchkovaVA, DelpeutS, MateoM, et al. (2009) Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol 83: 9596–9601.
21. DolnikO, VolchkovaV, GartenW, CarbonnelleC, BeckerS, et al. (2004) Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J 23: 2175–2184.
22. VolchkovVE, BeckerS, VolchkovaVA, TernovojVA, KotovAN, et al. (1995) GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214: 421–430.
23. ZakiSR, GoldsmithCS (1999) Pathologic features of filovirus infections in humans. Curr Top Microbiol Immunol 235: 97–116.
24. FeldmannH, GeisbertTW (2011) Ebola haemorrhagic fever. Lancet 377: 849–862.
25. TakadaA (2012) Filovirus tropism: cellular molecules for viral entry. Front Microbiol 3: 34.
26. BrayM, GeisbertTW (2005) Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 37: 1560–1566.
27. MartinezO, JohnsonJC, HonkoA, YenB, ShabmanRS, et al. (2013) Ebola virus exploits a monocyte differentiation program to promote its entry. J Virol 87: 3801–3814.
28. GuptaM, MahantyS, AhmedR, RollinPE (2001) Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 284: 20–25.
29. MahantyS, HutchinsonK, AgarwalS, McRaeM, RollinPE, et al. (2003) Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 170: 2797–2801.
30. LubakiNM, IlinykhP, PietzschC, TigabuB, FreibergAN, et al. (2013) The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J Virol 87: 7471–7485.
31. Wahl-JensenV, KurzS, FeldmannF, BuehlerLK, KindrachukJ, et al. (2011) Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis 5: e1359.
32. Wahl-JensenV, KurzSK, HazeltonPR, SchnittlerHJ, StroherU, et al. (2005) Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol 79: 2413–2419.
33. RubinsKH, HensleyLE, Wahl-JensenV, Daddario DiCaprioKM, YoungHA, et al. (2007) The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol 8: R174.
34. CaescuCI, JeschkeGR, TurkBE (2009) Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem J 424: 79–88.
35. YangZY, DuckersHJ, SullivanNJ, SanchezA, NabelEG, et al. (2000) Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med 6: 886–889.
36. ChanSY, MaMC, GoldsmithMA (2000) Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol 81: 2155–2159.
37. VolchkovVE, ChepurnovAA, VolchkovaVA, TernovojVA, KlenkHD (2000) Molecular characterization of guinea pig-adapted variants of Ebola virus. Virology 277: 147–155.
38. EzekowitzRA (2003) Role of the mannose-binding lectin in innate immunity. J Infect Dis 187 Suppl 2S335–339.
39. ThielS, JensenL, DegnSE, NielsenHJ, GalP, et al. (2012) Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components. Clin Exp Immunol 169: 38–48.
40. KilpatrickDC (2002) Mannan-binding lectin and its role in innate immunity. Transfus Med 12: 335–352.
41. TakahashiK, IpWE, MichelowIC, EzekowitzRA (2006) The mannose-binding lectin: a prototypic pattern recognition molecule. Curr Opin Immunol 18: 16–23.
42. MichelowIC, DongM, MungallBA, YantoscaLM, LearC, et al. (2010) A novel L-ficolin/mannose-binding lectin chimeric molecule with enhanced activity against Ebola virus. J Biol Chem 285: 24729–24739.
43. BrudnerM, KarpelM, LearC, ChenL, YantoscaLM, et al. (2013) Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors. PLoS One 8: e60838.
44. FuchsA, PintoAK, SchwaebleWJ, DiamondMS (2011) The lectin pathway of complement activation contributes to protection from West Nile virus infection. Virology 412: 101–109.
45. FuchsA, LinTY, BeasleyDW, StoverCM, SchwaebleWJ, et al. (2010) Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe 8: 186–195.
46. JiX, OlingerGG, ArisS, ChenY, GewurzH, et al. (2005) Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol 86: 2535–2542.
47. MichelowIC, LearC, ScullyC, PrugarLI, LongleyCB, et al. (2011) High-dose mannose-binding lectin therapy for Ebola virus infection. J Infect Dis 203: 175–179.
48. DubeD, SchornbergKL, ShoemakerCJ, DelosSE, StantchevTS, et al. (2010) Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci U S A 107: 16637–16642.
49. MarziA, MollerP, HannaSL, HarrerT, EisemannJ, et al. (2007) Analysis of the interaction of Ebola virus glycoprotein with DC-SIGN (dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) and its homologue DC-SIGNR. J Infect Dis 196 Suppl 2S237–246.
50. Babovic-VuksanovicD, SnowK, TenRM (1999) Mannose-binding lectin (MBL) deficiency. Variant alleles in a midwestern population of the United States. Ann Allergy Asthma Immunol 82: 134–141, 134-138-141 quiz 142–133..
51. GarredP, LarsenF, SeyfarthJ, FujitaR, MadsenHO (2006) Mannose-binding lectin and its genetic variants. Genes Immun 7: 85–94.
52. OkumuraA, PithaPM, YoshimuraA, HartyRN (2010) Interaction between Ebola virus glycoprotein and host toll-like receptor 4 leads to induction of proinflammatory cytokines and SOCS1. J Virol 84: 27–33.
53. Ganley-LealLM, LiangY, Jagannathan-BogdanM, FarrayeFA, NikolajczykBS (2010) Differential regulation of TLR4 expression in human B cells and monocytes. Mol Immunol 48: 82–88.
54. MuzioM, BosisioD, PolentaruttiN, D'AmicoG, StoppacciaroA, et al. (2000) Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J Immunol 164: 5998–6004.
55. ZaremberKA, GodowskiPJ (2002) Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 168: 554–561.
56. ShimizuT, NishitaniC, MitsuzawaH, ArikiS, TakahashiM, et al. (2009) Mannose binding lectin and lung collectins interact with Toll-like receptor 4 and MD-2 by different mechanisms. Biochim Biophys Acta 1790: 1705–1710.
57. WangM, ChenY, ZhangY, ZhangL, LuX, et al. (2011) Mannan-binding lectin directly interacts with Toll-like receptor 4 and suppresses lipopolysaccharide-induced inflammatory cytokine secretion from THP-1 cells. Cell Mol Immunol 8: 265–275.
58. MaYJ, KangHJ, KimJY, GarredP, LeeMS, et al. (2013) Mouse mannose-binding lectin-A and ficolin-A inhibit lipopolysaccharide-mediated pro-inflammatory responses on mast cells. BMB Rep 46: 376–381.
59. MuzioM, PolentaruttiN, BosisioD, PrahladanMK, MantovaniA (2000) Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol 67: 450–456.
60. ZhangG, GhoshS (2000) Molecular mechanisms of NF-kappaB activation induced by bacterial lipopolysaccharide through Toll-like receptors. J Endotoxin Res 6: 453–457.
61. BrightbillHD, ModlinRL (2000) Toll-like receptors: molecular mechanisms of the mammalian immune response. Immunology 101: 1–10.
62. BaizeS, LeroyEM, GeorgesAJ, Georges-CourbotMC, CapronM, et al. (2002) Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128: 163–168.
63. HensleyLE, YoungHA, JahrlingPB, GeisbertTW (2002) Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett 80: 169–179.
64. BeutlerB (2002) Toll-like receptors: how they work and what they do. Curr Opin Hematol 9: 2–10.
65. StroherU, WestE, BuganyH, KlenkHD, SchnittlerHJ, et al. (2001) Infection and activation of monocytes by Marburg and Ebola viruses. J Virol 75: 11025–11033.
66. RyabchikovaEI, KolesnikovaLV, NetesovSV (1999) Animal pathology of filoviral infections. Curr Top Microbiol Immunol 235: 145–173.
67. Wahl-JensenVM, AfanasievaTA, SeebachJ, StroherU, FeldmannH, et al. (2005) Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol 79: 10442–10450.
68. GeisbertTW, YoungHA, JahrlingPB, DavisKJ, LarsenT, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol 163: 2371–2382.
69. HensleyLE, GeisbertTW (2005) The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb Haemost 94: 254–261.
70. RoyallJA, BerkowRL, BeckmanJS, CunninghamMK, MatalonS, et al. (1989) Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am J Physiol 257: L399–410.
71. WauquierN, BecquartP, PadillaC, BaizeS, LeroyEM (2010) Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 4
72. CillonizC, EbiharaH, NiC, NeumannG, KorthMJ, et al. (2011) Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection. J Virol 85: 9060–9068.
73. GrosethA, MarziA, HoenenT, HerwigA, GardnerD, et al. (2012) The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog 8: e1002847.
74. XieXH, LiuEM, YangXQ, LawHK, LiX, et al. (2008) [Toll-like receptor 4 expression and function of respiratory syncytial virus-infected airway epithelial cells]. Zhonghua Jie He He Hu Xi Za Zhi 31: 213–217.
75. TalG, MandelbergA, DalalI, CesarK, SomekhE, et al. (2004) Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 189: 2057–2063.
76. HaynesLM, MooreDD, Kurt-JonesEA, FinbergRW, AndersonLJ, et al. (2001) Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 75: 10730–10737.
77. BurzynD, RassaJC, KimD, NepomnaschyI, RossSR, et al. (2004) Toll-like receptor 4-dependent activation of dendritic cells by a retrovirus. J Virol 78: 576–584.
78. BukreyevA, YangL, FrickeJ, ChengL, WardJM, et al. (2008) The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J Virol 82: 12191–12204.
79. DaubeufB, MathisonJ, SpillerS, HuguesS, HerrenS, et al. (2007) TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 179: 6107–6114.
80. MoeJB, LambertRD, LuptonHW (1981) Plaque assay for Ebola virus. J Clin Microbiol 13: 791–793.
81. VolchkovVE, VolchkovaVA, MuhlbergerE, KolesnikovaLV, WeikM, et al. (2001) Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291: 1965–1969.
82. MateoM, CarbonnelleC, ReynardO, KolesnikovaL, NemirovK, et al. (2011) VP24 is a molecular determinant of Ebola virus virulence in guinea pigs. J Infect Dis 204 Suppl 3S1011–1020.